Necchi, Andrea Nishiyama, Hiroyuki Matsubara, Nobuaki Lee, Jae-Lyun Petrylak, Daniel P. de Wit, Ronald Drakaki, Alexandra Liepa, Astra M. Mao, Huzhang Bell-McGuinn, Katherine
...
Published in
BMC Urology
BackgroundTo evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC).MethodsRANGE—a randomized, double-blinded, phase 3 trial in patients with platinum-refractory aUC. Ramucirumab (10 mg/kg) plus docetaxel (75 mg/m2) or placebo ...
Merl, Man Yee Moye, Renee Chatterjee, Anindya Ogburn, Kenyon D
Published in
SAGE Open Medical Case Reports
Gastric and gastroesophageal junction adenocarcinomas have poor prognoses. Ramucirumab is considered a second-line standard of care for patients with these cancers. Patients may develop chemotherapy-induced adverse events, and physicians may benefit from greater familiarity with treatment management in the setting of common adverse events. We repor...
Ruzzo, Annamaria Graziano, Francesco Bagaloni, Irene Di Bartolomeo, Maria Prisciandaro, Michele Aprile, Giuseppe Ongaro, Elena Vincenzi, Bruno Perrone, Giuseppe Santini, Daniele
...
Published in
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
For energy production, cancer cells maintain a high rate of glycolysis instead of oxidative phosphorylation converting glucose into lactic acid. This metabolic shift is useful to survive in unfavorable microenvironments. We investigated whether a positive glycolytic profile (PGP) in gastric adenocarcinomas may be associated with unfavorable outcome...
Lang, Susanne M. Rachow, Tobias
Published in
Kompass Pneumologie
Objectives: Currently, combination therapy of ramucirumab (RAM) + docetaxel (DOC) must play a more important role as a second-line treatment. Epithelial growth factor receptor (EGFR) mutation accounts for around 50% of oncogenic driver mutations in patients with advanced non-small cell lung cancer (NSCLC) in Asian subsets. The number of brain metas...
de Moraes Neto, Jarbas Emílio Pereira, Felipe Neves, Raquel Leão de Barros, Nilana Meza Tenório Gil, Cristiane Damas Fernandes, Arthur Gustavo Watanabe, Sung Eun Song Meyer, Carsten Helmut Farah, Michel Eid Rodrigues, Eduardo Buchele
...
Published in
International Journal of Retina and Vitreous
BackgroundAnti-angiogenic drugs remain the mainstay therapy for several vascular retinal pathologies. The repurposing of approved anti-angiogenic drugs for use in ophthalmology can increase therapeutic options and reduce costs. The purpose of this study was to investigate the ocular safety profile of intravitreal (IVT) ramucirumab, an approved anti...
Effing, Sophie Marie Anne Gyawali, Bishal
Published in
EClinicalMedicine
Ramucirumab is a widely used cancer drug having gained six regulatory approvals in various advanced solid tumors. Thus, assessing the risk-benefit profile of such a commonly used drug across multiple tumor types is necessary to inform clinical and reimbursement decisions. To objectively assess the risks and benefits of ramucirumab in patients with ...
Graziano, Francesco Fischer, Nicholas W. Bagaloni, Irene Di Bartolomeo, Maria Lonardi, Sara Vincenzi, Bruno Perrone, Giuseppe Fornaro, Lorenzo Ongaro, Elena Aprile, Giuseppe
...
Published in
Cancers
Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with second-line Ramucirumab/Paclitaxel and 62 patients who received first-lin...
Furuya, Naoki Ito, Kentaro Sakaguchi, Tadashi Hida, Naoya Kakinuma, Kazutaka Morikawa, Kei Inoue, Takeo Komase, Yuko Hataji, Osamu Mineshita, Masamichi
...
Published in
Oncology
Objectives: Currently, combination therapy of ramucirumab (RAM) + docetaxel (DOC) must play a more important role as a second-line treatment. Epithelial growth factor receptor (EGFR) mutation accounts for around 50% of oncogenic driver mutations in patients with advanced non-small cell lung cancer (NSCLC) in Asian subsets. The number of brain metas...
Yen, Chia-Jui Kudo, Masatoshi Lim, Ho-Yeong Hsu, Chih-Hung Vogel, Arndt Brandi, Giovanni Cheng, Rebecca Nitu, Ioana Simona Abada, Paolo Hsu, Yanzhi
...
Published in
Liver Cancer
Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). We evaluated the efficacy and safety of ramucirumab in Asian and non-Asian patients with AFP...
Garon, Edward B. Winfree, Katherine B. Molife, Cliff Cui, Zhanglin Lin Arriola, Edurne Levy, Benjamin Mekhail, Tarek Pérol, Maurice
Published in
Supportive Care in Cancer
Purpose In REVEL, patients with advanced non-small-cell lung cancer (aNSCLC) and patients with increased tumor aggressiveness (rapid disease progression (RDP), platinum-refractory disease (PRD), and high symptom burden (HSB)) benefited from second-line treatment with ramucirumab plus docetaxel over placebo plus docetaxel. This post hoc analysis des...
